188 related articles for article (PubMed ID: 36481378)
1. Diagnosis of mycosis fungoides or Sézary syndrome after dupilumab use: A systematic review.
Jfri A; Smith JS; Larocca C
J Am Acad Dermatol; 2023 May; 88(5):1164-1166. PubMed ID: 36481378
[No Abstract] [Full Text] [Related]
2. Unmasking a masquerader: Mycosis fungoides unveiled after dupilumab treatment.
Joshi TP; Duvic M
J Am Acad Dermatol; 2023 Jun; 88(6):e305-e306. PubMed ID: 36858155
[No Abstract] [Full Text] [Related]
3. Survival and Prognostic Factors in Patients with Aggressive Cutaneous T-cell Lymphomas.
Franceschi J; Ehret M; Visseaux L; Durlach A; Barbe C; Durot É; Grange F
Acta Derm Venereol; 2022 Mar; 102():adv00676. PubMed ID: 35083494
[TBL] [Abstract][Full Text] [Related]
4. Treatment of mycosis fungoides and Sézary syndrome with romidepsin: a series of 32 cases from the French Study Group for Cutaneous Lymphoma.
Deschamps O; Ram-Wolff C; Beylot-Barry M; Grange F; Skowron F; Dereure O; Boulinguez S; Aubin F; Ingen-Housz-Oro S; Bagot M;
Br J Dermatol; 2019 Feb; 180(2):423-424. PubMed ID: 30298903
[No Abstract] [Full Text] [Related]
5. Primary Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sezary Syndrome.
Querfeld C; Zain J; Rosen ST
Cancer Treat Res; 2019; 176():225-248. PubMed ID: 30596221
[TBL] [Abstract][Full Text] [Related]
6. Benefit/risk Ratio of Low-dose Methotrexate in Cutaneous Lesions of Mycosis Fungoides and Sézary Syndrome.
Alenezi F; Girard C; Bessis D; Guillot B; Du-Thanh A; Dereure O
Acta Derm Venereol; 2021 Feb; 101(2):adv00384. PubMed ID: 33313939
[TBL] [Abstract][Full Text] [Related]
7. Dupilumab, Atopic Dermatitis, and Mycosis Fungoides-New Insights on an Evolving Story.
Guitart J
JAMA Dermatol; 2023 Nov; 159(11):1177-1178. PubMed ID: 37851433
[No Abstract] [Full Text] [Related]
8. Dupilumab Treatment in Two Patients with Cutaneous T-cell Lymphomas.
Lazaridou I; Ram-Wolff C; Bouaziz JD; Bégon E; Battistella M; Rivet J; Jachiet M; Bagot M; de Masson A
Acta Derm Venereol; 2020 Sep; 100(16):adv00271. PubMed ID: 32556342
[No Abstract] [Full Text] [Related]
9. Changes to Registered and Pivotal Clinical Trials after the 2011 Tri-Societies Guidelines for Clinical Endpoints and Response Criteria in Mycosis Fungoides and Sézary Syndrome.
Gunter SJ; Kim EJ
J Invest Dermatol; 2024 Apr; 144(4):855-861.e1. PubMed ID: 37925066
[TBL] [Abstract][Full Text] [Related]
10. Spotlight on Mogamulizumab-Kpkc for Use in Adults with Relapsed or Refractory Mycosis Fungoides or Sézary Syndrome: Efficacy, Safety, and Patient Selection.
Blackmon AL; Pinter-Brown L
Drug Des Devel Ther; 2020; 14():3747-3754. PubMed ID: 32982179
[TBL] [Abstract][Full Text] [Related]
11. Real-world experience of using mogamulizumab in relapsed/refractory mycosis fungoides/Sézary syndrome.
Molloy K; Vico C; Ortiz-Romero PL; Scarisbrick JJ
Br J Dermatol; 2021 May; 184(5):978-981. PubMed ID: 33314065
[No Abstract] [Full Text] [Related]
12. Advancements in the treatment of mycosis fungoides and Sézary syndrome: monoclonal antibodies, immunotherapies, and Janus kinase inhibitors.
Quadri I; Reneau JC; Hanel W; Chung CG
Front Immunol; 2023; 14():1291259. PubMed ID: 38022633
[TBL] [Abstract][Full Text] [Related]
13. Mogamulizumab in the treatment of advanced mycosis fungoides and Sézary syndrome: safety and efficacy.
Lewis DJ; Rook AH
Expert Rev Anticancer Ther; 2020 Jun; 20(6):447-452. PubMed ID: 32320304
[TBL] [Abstract][Full Text] [Related]
14. Intralesional TTI-621, a novel biologic targeting the innate immune checkpoint CD47, in patients with relapsed or refractory mycosis fungoides or Sézary syndrome: a multicentre, phase 1 study.
Querfeld C; Thompson JA; Taylor MH; DeSimone JA; Zain JM; Shustov AR; Johns C; McCann S; Lin GHY; Petrova PS; Uger RA; Molloy N; Shou Y; Akilov OE
Lancet Haematol; 2021 Nov; 8(11):e808-e817. PubMed ID: 34627593
[TBL] [Abstract][Full Text] [Related]
15. State of the art therapy of mycosis fungoides and Sézary syndrome.
Kemme DJ; Bunn PA
Oncology (Williston Park); 1992 Feb; 6(2):31-42; discussion 44, 47-8. PubMed ID: 1532501
[TBL] [Abstract][Full Text] [Related]
16. Diagnosing mycosis fungoides after initiation of therapy with dupilumab: a case report and literature review.
Yan D; Ramachandran V; Weston G; Kim RH; Latkowski JA
Int J Dermatol; 2023 Sep; 62(9):e500-e503. PubMed ID: 36946434
[No Abstract] [Full Text] [Related]
17. CD30
Ellis A; Christensen LF; Sharma T; Meyerson H; Kord H; Cooper KD
J Am Acad Dermatol; 2021 Feb; 84(2):530-532. PubMed ID: 32437721
[No Abstract] [Full Text] [Related]
18. Mycosis fungoides and Sézary syndrome following dupilumab treatment: experience of two Italian tertiary care centres.
Buffon S; Alberti Violetti S; Avallone G; Venegoni L; Marzano AV; Mastorino L; Fava P; Ribero S; Quaglino P; Ortoncelli M; Ferrucci SM
Clin Exp Dermatol; 2023 Nov; 48(12):1376-1378. PubMed ID: 37596961
[No Abstract] [Full Text] [Related]
19. Comment on "Diagnostic testing of eczematous dermatitis with incomplete response to dupilumab".
Cohen JM; Damsky W; Girardi M
J Am Acad Dermatol; 2022 Dec; 87(6):e241-e242. PubMed ID: 35933070
[No Abstract] [Full Text] [Related]
20. Extracorporeal Photopheresis in the Treatment of Mycosis Fungoides and Sézary Syndrome.
Zic JA
Dermatol Clin; 2015 Oct; 33(4):765-76. PubMed ID: 26433848
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
